Testing eprolidone in chronic heart failure patients
Part of Heart & circulation clinical trials.
This early-phase study tests whether eprolidone (a heart-related medicine) can help regulate the body’s immune response in people with chronic congestive heart failure. Participants will get standard heart failure treatment, with some also taking eprolidone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign an informed consent form and agree to study procedures
- You have chronic congestive heart failure that matches NYHA class I or II
- Your heart pumping strength (LVEF) is 45% or lower from an RNVG scan
- You must be between 18 and 80 years old
- Your kidney function and blood tests must be within safe limits (creatinine ≤ 2.5 mg/dL, potassium ≤ 5.0 mmol/L)
- You should not be pregnant or breastfeeding during the study, and you should not have certain serious other illnesses or medication conflicts
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for people with heart failure and severely reduced kidney function. It aims to see if the treatment can help protect both the heart and kidneys.
This study looks at how mineralocorticoid-related hormone signaling affects small heart blood vessels and how efficiently the heart works in people with high blood pressure. It may help doctors understand which treatments could improve heart function in hypertension.
This trial tests an investigational medicine called CRD-4730 (taken as a pill) to see if it can improve heart function and symptoms in people with heart failure and a reduced pumping ability. It may help you feel better and slow the progression of your condition.
This Phase 2 study tests whether eplerenone can improve outcomes after a heart attack (or similar heart injury) when coronary angiography shows no blocked heart arteries. It focuses on people with added cardiovascular risk factors and evaluates how well the treatment works for heart recovery and strain on the heart.
This trial tests an investigational drug called CK-4021586 for people with heart failure with preserved ejection fraction (HFpEF). It aims to see if the drug is safe and well-tolerated. You may qualify if you are 40 to 85, have heart failure symptoms, and have a heart that pumps well but shows signs of strain.
This study tests an experimental drug called LY3971297 to see if it can help people with chronic heart failure. It aims to find out if the drug is safe and if it improves heart function.
Hear when a new Chronic Heart Failure Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.